An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease

Trial Profile

An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Adalimumab (Primary) ; Azathioprine; Prednisone
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms CALM
  • Sponsors AbbVie
  • Most Recent Events

    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
    • 31 Oct 2017 Primary endpoint (Rate of mucosal healing as defined by the Crohns Disease Endoscopic Index of Severity (CDEIS) score at 48 weeks after Randomization) has been met, according the results published in The Lancet.
    • 31 Oct 2017 Results published in The Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top